百濟神州(06160.HK)將在第63屆ASH年會公佈百悦澤®治療慢性淋巴細胞白血病臨牀數據
格隆匯11月5日丨百濟神州(06160.HK)於2021年11月4日(美國東部時間)宣佈,將在第63屆美國血液學會(ASH)年會及其展會上公佈血液腫瘤研究項目的臨牀結果和真實世界數據,其中包括兩份關於臨牀3期SEQUOIA試驗的口頭報吿,該試驗對比了百悦澤® (澤布替尼)與苯達莫司汀聯合利妥昔單抗(B+R),用於治療初治(TN)慢性淋巴細胞白血病(CLL)或小淋巴細胞淋巴瘤(SLL)患者的數據。 ASH會議將於2021年12月11至14日在佐治亞州亞特蘭大市以線上線下結合的形式舉行。
百濟神州血液學首席醫學官黃蔚娟醫學博士表示:“SEQUOIA試驗的陽性結果結合ALPINE的結果,證明百悦澤®可以改善CLL患者治療效果。今年ASH年會上呈現的數據,讓我們更加堅信百悦澤®的差異化設計能夠為血液腫瘤患者,包括那些在使用其他BTK抑制劑時終止治療的患者,帶來臨牀獲益。我們期待在亞特蘭大與醫學界分享關於我們血液學產品組合臨牀進展的更多細節。”
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.